Clinical evaluation of roxithromycin: A double-blind, placebo-controlled and crossover trial in patients with acne vulgaris


Ferahbas A. , utas s. , aykol d. , borlu m. , uksal u.

JOURNAL OF DERMATOLOGY, cilt.31, ss.6-9, 2004 (SCI İndekslerine Giren Dergi)

Özet

We clinically evaluated roxithromycin (ROM) in a double blind, placebo-controlled, and crossover trial in patients with inflammatory acne. Patients with inflammatory acne who were attending our outpatient clinic for treatment and who had not received topical or systemic treatment for the previous month were enrolled in this study. Patients were randomly separated into two groups. Group I consisted of 26 patients. The patients received 2 x 150 mg/day ROM orally in the first period and 2 x I placebo tablets/day in the second period. Group 11 consisted of 20 patients. These patients received 2 x I placebo tablets/day in the first period and 2 x 150 mg/day ROM orally in the second period. The first period was the first four weeks, and then there was a washout period of two weeks (5th and 6th). The second period was the next four weeks (7th to 10th weeks) after the washout period. Median acne scores had clearly decreased in both groups at the end of the study. Differences of median acne scores were statistically significant in both groups between at baseline and at the end of the study (p< 0.001). The results showed that ROM is a safe and effective alternative in the treatment of inflammatory acne with few side effects and good compliance.